Safety and Efficacy of Remimazolam Compared to Placebo and Midazolam for Moderate Sedation during Bronchoscopy.
, Yarmus LB
, Schippers F
, Ostroff R
, Chen A
, Akulian J
, Wahidi M
, Shojaee S
, Tanner NT
, Callahan SP
, Feldman G
, Lorch DG
, Ndukwu I
, Pritchett MA
, Silvestri GA
Full Text Sources
While the complexity of flexible bronchoscopy has increased, standard options for moderate sedation medications have not changed in three decades. There is need to improve moderate sedation while maintaining safety. Remimazolam was developed to address shortcomings of current sedation strategies.
PMID: 30292760 [PubMed - as supplied by publisher]
- A Placebo- and Midazolam-Controlled, Phase I, Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056): Part I. Safety, Efficacy, and Basic Pharmacokinetics.
- A Placebo and Midazolam-Controlled Phase I Single Ascending Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056). Part II: Population Pharmacokinetic and Pharmacodynamic Modeling and Simulation.
- A Phase IIa, Randomized, Double-Blind Study of Remimazolam (CNS 7056) Versus Midazolam for Sedation in Upper Gastrointestinal Endoscopy.
- [Review] Midazolam for sedation before procedures.
- A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy.